Surgery on diseased or cirrhotic livers is generally associated with higher morbidity and mortality. The overall recurrence rate after resection is 50–60%. The Singapore Liver Cancer Recurrence  score can be used to estimate risk of recurrence after surgery. Liver transplantation
Liver transplantation, replacing the diseased liver with a cadaveric or a living donor liver, plays an increasing role in treatment of HCC. Although outcomes following liver transplant were initially poor (20%–36% survival rate), outcomes have significantly improved with improvement in surgical techniques and adoption of the Milan criteria at US transplantation centers. Expanded Shanghai criteria in China have resulted in overall survival and disease-free survival rates similar to those achieved using the Milan criteria. Studies from the late 2000s obtained higher survival rates ranging from 67% to 91%.The risks of liver transplantation extend beyond risk of the procedure itself. The immunosuppressive medication  required after surgery to prevent rejection of the donor liver also impairs the bodys natural ability to combat dysfunctional cells. If the tumor has spread undetected outside the liver before the transplant, the medication effectively increases the rate of disease progression and decreases survival. With this in mind, liver transplant "can be a curative approach for patients with advanced HCC without extrahepatic metastasis". In fact, among patients with compensated cirrhosis, transplantation is not associated with improved survival compared to hepatectomy, but instead is significantly more expensive. Patient selection is considered a major key for success. Ablation
Radiofrequency ablation (RFA) uses high-frequency radio waves to destroy tumor by local heating.
See also
Hemihypertrophy
Oncovirus
Portal hypertension

References
Further reading
"Long-term results of liver transplantation for hepatocellular carcinoma: an update of the University of Padova experience". September 23, 2013. Retrieved 6 February 2014. Bruix, Jordi; Sherman, Morris; Practice Guidelines Committee (November 2005). "Management of hepatocellular carcinoma". Hepatology. 42 (5): 1208–1236. doi:10.1002/hep.20933. PMID 16250051. S2CID 5106445. Liu, Chi-leung, M.D., "Hepatic Resection for Hepatocellular Carcinoma", The Hong Kong Medical Diary, Vol.10 No.12, December 2005 Medical Bulletin

External links
Blue Faery: The Adrienne Wilson Liver Cancer Association (hepatocellular carcinoma patient support site)
NCI Liver Cancer Homepage